Scaling back psoriasis
Psoriasis occurs in many forms, but by far the most common type of psoriasis is the chronic plaque type (up to 90% of presentations), also known as psoriasis vulgaris or chronic plaque psoriasis.
It is prevalent in up to 2-3% of the adult population.
The role of the GP is central in care of patients with this complex condition, including coordinating dermatologist and pharmacist advice.
It is important for the GP to give a dermatologist appropriate feedback on the outcomes of therapy for an individual patient, especially when systemic and biologic prescriptions are initiated and followed.
This clinical audit will allow you to review your current management of patients with psoriasis, and compare it with best practice guidelines.
By completing this audit, GPs will be able to:
- Describe clinical signs and symptoms of psoriasis and update knowledge on relevant differential diagnosis.
- Accurately assess patients with psoriasis for disease severity, impact on QOL, whether patients have psoriatic arthritis, and presence of co-morbidities.
- Update knowledge on new treatment options available in psoriasis management and clinical benefits of combination products where necessary.
- Implement step-wise treatment plans for patients with sub-optimal control of psoriasis.
- Identify patients with sub-optimal control of psoriasis despite monotherapy on TCS, systemics, phototherapy or biologics.
On successful completion of this second audit and evaluation, GPs will be eligible for 40 Category 1 QI&CPD points from the RACGP, or 30 PRPD points from ACRRM.
This audit qualifies as a Quality Improvement activity.